<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36168148</PMID><DateCompleted><Year>2023</Year><Month>01</Month><Day>03</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2160-7648</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Clinical pharmacology in drug development</Title><ISOAbbreviation>Clin Pharmacol Drug Dev</ISOAbbreviation></Journal><ArticleTitle>Pharmacokinetics, Bioavailability, and Swallowing Safety With Riluzole Oral Film.</ArticleTitle><Pagination><StartPage>57</StartPage><EndPage>64</EndPage><MedlinePgn>57-64</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/cpdd.1168</ELocationID><Abstract><AbstractText>Dysphagia is highly prevalent in patients with amyotrophic lateral sclerosis (ALS). Riluzole is a US Food and Drug Administration-approved treatment for ALS. Riluzole oral film (ROF; Exservan&#x2122;) contains riluzole in a polymer-based film matrix. The ROF is administered by placing on the tongue, where it dissolves and the drug is ingested with the saliva. Two clinical trials assessed the safety and tolerability of the ROF. Bioavailability and pharmacokinetics (PK) were evaluated in an open-label, randomized, single-dose, replicate crossover study of 50&#xa0;mg of ROF and riluzole 50-mg tablets in 32 healthy volunteers. The second study was a videofluoroscopic swallowing examination conducted with nine patients with ALS before and after receiving a single dose of 50&#xa0;mg of ROF. The primary outcome was change on penetration-aspiration scale (PAS) scores from pre- to post-dose. Overall, the PK parameters for ROF and riluzole tablets were comparable between treatments and administrations when administered under fasting conditions. Administration of ROF with food resulted in a 15% reduction in area under the curve and a 45% reduction in maximum serum concentration. A total of 44 treatment-emergent adverse events (AEs) were reported in the study; all were mild in severity. No serious AEs were observed and no subjects discontinued due to AEs. In the swallowing study, very little numerical or categorical change was observed following the dose of ROF. No evidence of deterioration of swallowing function was observed post-dose. The ROF was bioequivalent to riluzole tablets, was well tolerated, and had no detrimental effect on swallowing.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wymer</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Apple</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Antoinette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hill</LastName><ForeName>Bryan Alan</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Mitsubishi Tanabe Pharma America, Inc., Jersey City, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Pharmacol Drug Dev</MedlineTA><NlmUniqueID>101572899</NlmUniqueID><ISSNLinking>2160-763X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>7LJ087RS6F</RegistryNumber><NameOfSubstance UI="D019782">Riluzole</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019782" MajorTopicYN="Y">Riluzole</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001682" MajorTopicYN="N">Biological Availability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003679" MajorTopicYN="N">Deglutition</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic Lateral Sclerosis</Keyword><Keyword MajorTopicYN="N">Clinical Trials</Keyword><Keyword MajorTopicYN="N">Drug Development</Keyword><Keyword MajorTopicYN="N">Drug-food Interactions</Keyword><Keyword MajorTopicYN="N">Dysphagia</Keyword><Keyword MajorTopicYN="N">Neurology</Keyword><Keyword MajorTopicYN="N">Pharmacokinetics and Drug Metabolism</Keyword><Keyword MajorTopicYN="N">Riluzole</Keyword><Keyword MajorTopicYN="N">Swallow</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>8</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>28</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36168148</ArticleId><ArticleId IdType="pmc">PMC10087659</ArticleId><ArticleId IdType="doi">10.1002/cpdd.1168</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al&#x2010;Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162&#x2010;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris SP, Likanje MN, Andrews JA. Amyotrophic lateral sclerosis: update on clinical management. Curr Opin Neurol. 2022;33(5):641&#x2010;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">32868602</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Jorgenson JA, Newhouse BJ, Shefner JM, Agnese W. Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy &#x2010; a roundtable discussion. Am J Manag Care. 2018;24(9 suppl):S175&#x2010;S186.</Citation><ArticleIdList><ArticleId IdType="pubmed">29693363</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, et&#xa0;al. Amyotrophic lateral sclerosis. Lancet. 2011;377(9769):942&#x2010;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al&#x2010;Chalabi A, Chio A, et&#xa0;al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Robison R, DiBiase L, Ashley A, et&#xa0;al. Swallowing safety and efficiency impairment profiles in individuals with amyotrophic lateral sclerosis. Dysphagia. 2022;37(3):644&#x2010;654.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8617061</ArticleId><ArticleId IdType="pubmed">34037850</ArticleId></ArticleIdList></Reference><Reference><Citation>Writing Group; Edaravone (MCI&#x2010;186) ALS 19 Study Group. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double&#x2010;blind, placebo&#x2010;controlled trial. Lancet Neurol. 2017;16(7):505&#x2010;512.</Citation><ArticleIdList><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med. 1994;330(9):585&#x2010;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose&#x2010;ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet. 1996;347(9013):1425&#x2010;1431.</Citation><ArticleIdList><ArticleId IdType="pubmed">8676624</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Liboux A, Lefebvre P, Le Roux Y, et&#xa0;al. Single&#x2010; and multiple&#x2010;dose pharmacokinetics of riluzole in white subjects. J Clin Pharmacol. 1997;37(9):820&#x2010;827.</Citation><ArticleIdList><ArticleId IdType="pubmed">9549636</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Liboux A, Cachia JP, Kirkesseli S, et&#xa0;al. A comparison of the pharmacokinetics and tolerability of riluzole after repeat dose administration in healthy elderly and young volunteers. J Clin Pharmacol. 1999;39(5):480&#x2010;486.</Citation><ArticleIdList><ArticleId IdType="pubmed">10234595</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanderink GJ, Bournique B, Stevens J, Petry M, Martinet M. Involvement of human CYP1A isoenzymes in the metabolism and drug interactions of riluzole in vitro. J Pharmacol Exp Ther. 1997;282(3):1465&#x2010;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">9316860</ArticleId></ArticleIdList></Reference><Reference><Citation>Qureshi I, Lovegren M, Wirtz V, et&#xa0;al. A pharmacokinetic bioequivalence study comparing sublingual riluzole (BHV&#x2010;0223) and oral tablet formulation of riluzole in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9(4):476&#x2010;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">31610101</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron D. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2010;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa MM. Videofluoroscopy: the gold standard exam for studying swallowing and its dysfunction. Arq Gastroenterol. 2010;47(4):327&#x2010;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">21225139</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin&#x2010;Harris B, Jones B. The videofluorographic swallowing study. Phys Med Rehabil Clin N Am. 2008;19(4):769&#x2010;785, viii.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2586156</ArticleId><ArticleId IdType="pubmed">18940640</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, et&#xa0;al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1&#x2010;2):13&#x2010;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Crary MA, Mann GD, Groher ME. Initial psychometric assessment of a functional oral intake scale for dysphagia in stroke patients. Arch Phys Med Rehabil. 2005;86(8):1516&#x2010;1520.</Citation><ArticleIdList><ArticleId IdType="pubmed">16084801</ArticleId></ArticleIdList></Reference><Reference><Citation>Belafsky PC, Mouadeb DA, Rees CJ, et&#xa0;al. Validity and reliability of the eating assessment tool (EAT&#x2010;10). Ann Otol Rhinol Laryngol. 2008;117(12):919&#x2010;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">19140539</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>